Previous Close | 0.2842 |
Open | 0.2850 |
Bid | 0.2700 x 900 |
Ask | 0.2984 x 1200 |
Day's Range | 0.2410 - 0.2880 |
52 Week Range | 0.2300 - 2.2000 |
Volume | |
Avg. Volume | 102,055 |
Market Cap | 2.283M |
Beta (5Y Monthly) | 1.56 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.3410 |
Earnings Date | May 10, 2023 - May 15, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5.00 |
Following the decision to discontinue the development of pipeline candidates, Bellicum Pharmaceuticals (BLCM) is left with no candidate in clinical development. The stock is down 50% post the news.
Here is how Bellicum Pharmaceuticals (BLCM) and Chemed (CHE) have performed compared to their sector so far this year.
HOUSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), today announced its decision to discontinue its ongoing Phase 1/2 clinical trials evaluating the safety and preliminary efficacy of its GoCAR-T cell product candidates in combination with rimiducid in heavily pre-treated cancer patients. The trials for BPX-601 and BPX-603 are being discontinued following the Company’s assessment of the risk/benefit profile of BPX-601 in combination with rimiducid. The most